Sun Pharmaceutical Industries is currently trading at Rs. 1751.00, up by 131.05 points or 8.09% from its previous closing of Rs. 1619.95 on the BSE.

The scrip opened at Rs. 1632.50 and has touched a high and low of Rs. 1,766.65 and Rs. 1621.00 respectively. So far 523952 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1850.95 on 02-May-2025 and a 52 week low of Rs. 1547.25 on 26-Sep-2025.

Last one week high and low of the scrip stood at Rs. 1,819.15 and Rs. 1614.20 respectively. The current market cap of the company is Rs. 414689.06 crore.

The promoters holding in the company stood at 54.48%, while Institutions and Non-Institutions held 37.03% and 8.48% respectively.

Sun Pharmaceutical Industries and Organon & Co. have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for $14.00 per share in an all cash transaction with an enterprise valuation of $11.75 billion.

Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. The proposed acquisition of Organon is aligned with Sun Pharma’s strategy of growing its Innovative Medicines business. The combined company becomes a stronger player in Established Brands /Branded Generics business. The deal also enables Sun Pharma’s entry into biosimilars as a Top-10 global player. Organon’s portfolio, global footprint and strong stakeholder relationships shall complement Sun Pharma’s existing strengths and enhance long term value creation.

The transaction has been approved by the Boards of Directors of both Sun Pharma and Organon and is subject to customary closing conditions, including receipt of required regulatory approvals and approval by Organon stockholders.

Upon successful consummation of the transaction, Sun Pharma is poised to be among the top 25 global pharmaceutical companies with combined revenue of $12.4 billion; a leading player in Established Brands/Branded Generics; a more Innovative Medicines focused company with 27% revenue share; a top 3 company in global Women’s Health, creating a commercial platform for future growth; the 7th Largest global biosimilar player; a company with presence in 150 countries, with 18 large markets, each generating over $100 million revenues.

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.